结核性支气管扩张合并感染547例临床分析  

Analysis of 547 cases of infections secondary to tuberculous bronchiectasis

作　　者：陈惠芬[1] 赵新国[1] 罗文侗[2] 

机构地区：[1]江苏省无锡市传染病医院肺病诊治中心,214007 [2]第二军医大学长征医院呼吸内科

出　　处：《中国感染与化疗杂志》2009年第6期412-415,共4页Chinese Journal of Infection and Chemotherapy

摘　　要：目的探讨结核性支气管扩张合并感染患者的病原菌、药敏情况及临床特点与治疗。方法对无锡市传染病医院肺科病区2007年1月—2009年1月资料较完整的结核性支气管扩张合并感染住院患者547例的临床表现、痰细菌学检查、药敏情况进行回顾性分析。结果547例痰普通培养阳性率27.0%,真菌培养阳性率10.3%,结核菌痰涂片抗酸杆菌阳性率6.8%。结论结核性支气管扩张合并感染,以革兰阴性杆菌感染为主,在抗菌药物应用时应选择对革兰阴性杆菌有效的药物,一般应联合用药。Objective To investigate the bacterial and clinical features, antibiotic susceptibility and therapy of infections in patients with tuberculous bronchiectasis. Methods The clinical manifestations, bacteriological findings of sputum, and antimicrobial susceptibility of the isolated pathogens were analyzed retrospectively by reviewing the medical records of 547 patients with infection secondary to tuberculous bronchiectasis. These patients were hospitalized in the pulmonary ward of Wuxi Hospital of Infectious Diseases from January 2007 to January 2009. Results Sputum culture was positive for pathogenic bacteria in 29.0% of the 547 cases, positive for fungi in 10.3% of the 547 cases. The prevalence of smear-positive active pulmonary tuberculosis was 18 %. Conclusions The pathogens in the infections secondary to tuberculous broncbiectasis were primarily gram negative bacteria. The antimicrobial therapy should cover antibiotics active for gram-negative organisms. Combination antimicrobial therapy is usually a good choice.

关 键 词：肺结核 支气管扩张 感染 病原菌 

分 类 号：R521.1[医药卫生—内科学]